46 completed, 11 recruiting, 7 active not recruiting, 7 not yet recruiting. 44 Phase 2, 27 Phase 3, 12 Phase 1, 3 Not applicable, 1 Early Phase 1.
Follow bedaquiline: new trials by email Literature Review of bedaquiline trials Research Report on bedaquiline
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours), Ceftriaxone for Injection, Amoxicillin - Mycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Infection | Phase 2 | Not yet recruiting | The University of Queensland | 300 | 2027-04-01 | 2026-03-20 |
| A 6-Month MDR-END Plus Regimen for Rifampicin-Resistant Tuberculosis MDR-END Plus regimen, Standard-of-care (SoC) treatment - Rifampicin-Resistant Tuberculosis | Phase 3 | Not yet recruiting | Seoul National University Hospital | 294 | 2026-10-01 | 2026-06-30 |
| Feasibility of the Application of a New Six-month Treatment for Multidrug-resistant Tuberculosis (MDR-TB) Patients in France (FAST-MDR) Bedaquiline Oral Tablet - MDR-TB, Tuberculosis Multi Drug Resistant Active | Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 55 | 2026-09-11 | 2026-09-16 |
| Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TB Bedaquiline, Isoniazid, rifapentine, Levofloxacin - Tuberculosis, Latent | Phase 2 / Phase 3 | Recruiting | Johns Hopkins University | 2530 | 2026-05-08 | 2026-10-20 |
| Bactericidal Activity and Safety of Nicotinamide in Combination With Bedaquiline, Pretomanid, and Linezolid in Drug-susceptible Pulmonary Tuberculosis Bedaquiline, pretomanid, linezolid, Nicotinamide (NAM) - Drug Susceptible Pulmonary Tuberculosis | Phase 2 | Suspended | Gates Medical Research Institute | 165 | 2026-04-17 | 2026-08-10 |
| Bactericidal Activity of TBD09 in Combination With Other Drugs in Pulmonary Tuberculosis Bedaquiline, pretomanid and TBD09, Bedaquiline, pretomanid and linezolid - Drug Susceptible Pulmonary Tuberculosis | Phase 2 | Recruiting | Gates Medical Research Institute | 150 | 2026-04-14 | 2026-07-30 |
| Pharmacokinetics of Antituberculosis Drugs in Breastfeeding Women Standard dose rifampicin, High dose rifampicin, Standard dose isoniazid - Tuberculosis Infection, Healthy Volunteer | Phase 1 | Not yet recruiting | McGill University Health Centre/Research Institute of the McGill University Health Centre | 60 | 2026-04-01 | 2026-02-10 |
| Bacteriophage Therapy for Mycobacterium Abscessus Pulmonary Infection Mycobacteriophage Muddy_HRMN0052, Amikacin Injection, Clofazimine - Non-Tuberculous Mycobacterial (NTM) Pneumonia, Mycobacterium Abscessus Infection | Phase 1 | Enrolling by invitation | Vancouver Coastal Health | 1 | 2026-01-11 | 2026-06-03 |
| A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis BPaQM, BPaLM, BPaQ - Pulmonary Tuberculosis | Phase 3 | Recruiting | Otsuka Pharmaceutical Development & Commercialization, Inc. | 532 | 2025-10-16 | 2026-05-06 |
| Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis Bedaquiline, Linezolid, Pretomanid - Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant | Phase 2 / Phase 3 | Recruiting | University of California, San Francisco | 400 | 2025-10-03 | 2026-09-02 |
| 6 Months of Bedaquiline(BDQ), Delamanid(DLM), Linezolid(LZD) and Levofloxacin(LFX) in RR-TB Patients in Hubei Province bedaquiline, Delamanid (DLM), Linezolid (LZD) - Treat to Target, Treatment Duration | Not applicable | Not yet recruiting | Wuhan Pulmonary Hospital | 52 | 2025-09-30 | 2025-09-30 |
| A Study on the Short-course Treatment Regimen Containing Pretomanid for Drug-resistant Tuberculosis bedaquiline, Pretomanid (Pa), linezolid - Efficacy and Safety | Not applicable | Not yet recruiting | Wuhan Pulmonary Hospital | 200 | 2025-09-01 | 2025-08-17 |
| Short-Course Regimen With Bedaquiline, Moxifloxacin and Pyrazinamide for Early Bactericidal Activity in Drug-Susceptible Tuberculosis Bedaquiline (B), Moxifloxacin, Pyrazinamide (PZA) - Tuberculosis, Pulmonary, Drug-Susceptible Pulmonary Tuberculosis | Phase 2 | Not yet recruiting | Shanghai Pulmonary Hospital, Shanghai, China | 45 | 2025-08-20 | 2025-08-19 |
| Ultra-Short Regimen for Elderly DS-TB Bedaquiline (B), Sitafloxacin (S), Linezolid (L) - Pulmonary Tuberculosis | Phase 3 | Not yet recruiting | Shenzhen Third People's Hospital | 300 | 2025-07-25 | 2025-07-22 |
| A PAN-USR TB Multi-Center Trial Bedaquiline (B), Sitafloxacin (S), Linezolid (L) - Pulmonary Tuberculosis | Phase 3 | Recruiting | Shenzhen Third People's Hospital | 610 | 2025-06-18 | 2025-12-01 |
| Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis Isoniazid, Rifampicin, Pyrazinamide - Pulmonary Tuberculosis | Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 315 | 2025-03-11 | 2026-10-19 |
| Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese Cohort bedaquiline, delamanid, linezolid - Drug-resistant Tuberculosis, Pulmonary Tuberculosis | Phase 3 | Active not recruiting | Huashan Hospital | 120 | 2024-11-27 | 2025-09-02 |
| Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB Ganfeborole, BTZ-043, Bedaquiline (B) - Pulmonary Tuberculosis | Phase 2 | Recruiting | University College, London | 2500 | 2024-01-09 | 2026-10-15 |
| Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort Bedaquiline, Delamanid, Contezolid - Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis | Phase 3 | Active not recruiting | Beijing Chest Hospital | 186 | 2023-12-22 | 2025-04-01 |
| Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible Tuberculosis Bedaquiline (BDQ), Clofazimine (CFZ), Pyrazinamide (PZA) - Tuberculosis, Pulmonary, HIV | Phase 2 | Active not recruiting | Brigham and Women's Hospital | 94 | 2023-11-24 | 2026-08-05 |
Showing 20 of 79. Sign in to see all of them.
Tuberculosis (36) · Tuberculosis, Pulmonary (34) · Tuberculosis, Multidrug-Resistant (28) · Extensively Drug-Resistant Tuberculosis (9) · HIV Infections (4) · Latent Tuberculosis (3) · Mycobacterium Infections, Nontuberculous (3) · Bacterial Infections (2) · Gram-Positive Bacterial Infections (2) · Infections (2) · Lung Diseases (2) · Breast Feeding (1) · Disease (1) · Leprosy (1) · Leprosy, Multibacillary (1)
Global Alliance for TB Drug Development (10) · National Institute of Allergy and Infectious Diseases (NIAID) (7) · Tibotec BVBA (5) · Janssen Research & Development, LLC (4) · Medecins Sans Frontieres, Netherlands (4) · Gates Medical Research Institute (3) · Janssen Infectious Diseases BVBA (3) · Beijing Chest Hospital (2) · Huashan Hospital (2) · Janssen Pharmaceutical K.K. (2) · Michael Hoelscher (2) · Médecins Sans Frontières, France (2) · Otsuka Pharmaceutical Development & Commercialization, Inc. (2) · Shanghai Jiatan Pharmatech Co., Ltd (2) · Shenzhen Third People's Hospital (2)
South Africa (42) · Philippines (11) · Uganda (11) · China (10) · Peru (10) · Tanzania (10) · Georgia (7) · India (7) · Brazil (6) · Russia (6) · Thailand (6) · Vietnam (6) · Haiti (5) · United States (5) · Belarus (4)
Andreas Diacon (2) · Carole Mitnick, Sc.D (2) · Kelly Dooley, MD (2) · Kelly Dooley, MD, PhD (2) · Lorenzo Guglielmetti, MD (2) · Morounfolu Olugbosi, MD (2) · A-Dong Shen, Master (1) · Andreas Diacon, MD (1) · Andrew Nunn, PhD (1) · Anneke Hesseling, M.D., Ph.D. (1) · Anthony Garcia-Pratts, MD (1)
PMID 36808186, PMID 25114140, PMID 26647431, PMID 36053506, PMID 36546625, PMID 37035978, PMID 37980911, PMID 38768617, PMID 16470119, PMID 16988514, PMID 18366444, PMID 18505852, PMID 18795962, PMID 18989231, PMID 19494215, PMID 20002783, PMID 20632458, PMID 21283017, PMID 22083071, PMID 22129166, PMID 22828481, PMID 23305215, PMID 23392467, PMID 25140958, PMID 25162818, PMID 25261418, PMID 25407158, PMID 25512422, PMID 25622149, PMID 25950206, PMID 25959631, PMID 26038418, PMID 26104205, PMID 26202768, PMID 26918544, PMID 26929418, PMID 27540363, PMID 29061739, PMID 29369162, PMID 29520730, PMID 29528944, PMID 30024924, PMID 30102705, PMID 30134297, PMID 30358179, PMID 30530925, PMID 30715324, PMID 30865791, PMID 31489678, PMID 31676905
2018 (2), 2008 (1), 2009 (1), 2014 (1), U01AI152980 (1), U01AI170426 (1)